Pancreatic Cancer Research

ResearcherThe Cancer Institute HospitalActive in the last 2 years

Atsushi Oba

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7315-0830; OpenAlex author ID A5026341464. Sources: OpenAlex.

Their work

Papers
62 (first author 15, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
178
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 4 papers · 2021: 5 papers · 2022: 11 papers · 2023: 11 papers · 2024: 4 papers · 2025: 15 papers · 2026: 10 papers

Papers 50 of 62

  1. Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer. First author DOI 10.1001/jamasurg.2026.1810↗
  2. Survival Impact After Resection for Postoperative Recurrence or Metastasis of Pancreatic Ductal Adenocarcinoma Analyzed Using a Time-Dependent Cox Regression M… Co-author DOI 10.1002/jhbp.70054↗
  3. Clinical significance of gadoxetate sodium-enhanced MRI for detecting liver metastasis in patients with pancreatic cancer: decadal real-world data analysis in … Co-author DOI 10.1007/s00535-026-02431-3↗
  4. Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies. Co-author DOI 10.1016/j.hpb.2025.12.001↗
  5. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  6. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  7. Tangential Versus Segmental Portomesenteric Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: An International Multicenter Cohort Study on S… Co-author DOI 10.1097/sla.0000000000006638↗
  8. Surgical Challenges Associated with Collateral Veins Formation in Pancreatic Cancer with Vein Resection. First author DOI 10.1245/s10434-025-18806-4↗
  9. ASO Author Reflections: Beware the Collaterals: Vein Formation Signals Higher Surgical Risk in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-025-18960-9↗
  10. ASO Visual Abstract: Surgical Challenges Associated with Collateral Veins Formation in Pancreatic Cancer with Vein Resection. First author DOI 10.1245/s10434-025-19046-2↗
  11. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  12. Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter… Co-author DOI 10.1002/ags3.70001↗
  13. Anatomical evaluation of the perinephric vein as a surgical landmark in minimally invasive distal pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s00464-025-12125-1↗
  14. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  15. Clinical implications of disappearing pancreatic cancer liver metastases: Lessons from colorectal liver metastases. Co-author DOI 10.1016/j.ejso.2025.109635↗
  16. Exploring the role of CA 19-9 dynamics in pancreatic cancer multidisciplinary treatment: Proposal of the PANC classification. First author DOI 10.1016/j.surg.2025.109783↗
  17. Pancreatic cancer. Co-author DOI 10.1016/s0140-6736(25)00261-2↗
  18. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  19. Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal comparative study. First author DOI 10.1093/bjsopen/zraf026↗
  20. Technique of Circumferential Divestment of the Superior Mesenteric Artery for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-17019-z↗
  21. ASO Author Reflections: Advancing the Superior Mesenteric Arterial Divestment for Locally Advanced Pancreatic Cancer: New Standard Procedure and Future Prospec… Co-author DOI 10.1245/s10434-025-17090-6↗
  22. Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy. First author DOI 10.1245/s10434-025-17407-5↗
  23. ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicator for Neoadjuvant Therapy. First author DOI 10.1245/s10434-025-17458-8↗
  24. Invited Editorial: Clinical Relevance of High-Grade Pancreatic Intraepithelial Neoplasia at the Pancreatic Transection Margin in Patients with Pancreatic Ducta… Co-author DOI 10.1245/s10434-025-17712-z↗
  25. Favorable Response Defined by CA19-9 Reduction After Neoadjuvant Treatment for Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18084-0↗
  26. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. First author DOI 10.1001/jamanetworkopen.2024.17625↗
  27. Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.pan.2024.10.001↗
  28. A proposal of ABCD metastasectomy criteria for synchronous/metachronous metastatic pancreatic cancer in the era of multidisciplinary treatment. Co-author DOI 10.1093/bjs/znad417↗
  29. Unique Biology of Pancreatic Ductal Adenocarcinoma Accompanied by Rapidly Impaired Diabetes: A Favorable Long-Term Survival Following Curative Resection. Co-author DOI 10.1245/s10434-023-14408-0↗
  30. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression. Co-author DOI 10.1002/cjp2.323↗
  31. Feasibility of laparoscopic radical antegrade modular pancreatosplenectomy (RAMPS) as a standard treatment for distal resectable pancreatic cancer. First author DOI 10.1007/s00423-023-02942-0↗
  32. New approach of circumferential lymph node dissection around the superior mesenteric artery for pancreatic cancer during pancreaticoduodenectomy (with video). Co-author DOI 10.1007/s00423-023-03159-x↗
  33. Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with e… Co-author DOI 10.1016/j.hpb.2022.09.012↗
  34. Intraoperative paraaortic lymph node sampling during resection for pancreatic cancer: evolving role in the modern chemotherapy era. First author DOI 10.1016/j.hpb.2023.05.366↗
  35. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… Co-author DOI 10.1016/j.pan.2023.06.005↗
  36. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery… Co-author DOI 10.1016/j.pan.2023.07.005↗
  37. Outcomes of lung oligometastasis in pancreatic cancer. Co-author DOI 10.1093/jjco/hyad111↗
  38. Serum DUPAN-2 could be an Alternative Biological Marker for CA19-9 Nonsecretors with Pancreatic Cancer. First author DOI 10.1097/sla.0000000000005395↗
  39. Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery. Co-author DOI 10.1245/s10434-023-13534-z↗
  40. Impact of sarcopenia on S1 adjuvant chemotherapy and prognosis in pancreatic cancer patients. Co-author DOI 10.5582/bst.2023.01209↗
  41. New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). Co-author DOI 10.1002/jhbp.1049↗
  42. Long-Term Outcome of Patients with Postoperative Refractory Diarrhea After Tailored Nerve Plexus Dissection Around the Major Visceral Arteries During Pancreato… Co-author DOI 10.1007/s00268-022-06457-5↗
  43. Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Cancer Database cohort analysis. Co-author DOI 10.1093/bjs/znac002↗
  44. Author response to: Comment on: Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Cancer Data… Co-author DOI 10.1093/bjs/znac340↗
  45. Prognosis Based Definition of Resectability in Pancreatic Cancer: A Road Map to New Guidelines. Co-author DOI 10.1097/sla.0000000000003859↗
  46. Diabetogenic liver metastasis from pancreatic cancer: a case report. Co-author DOI 10.1186/s40792-022-01582-8↗
  47. Impact of Tumor Size on the Outcomes of Patients with Resectable Distal Pancreatic Cancer: Lessons Learned from a Series of 158 Radical Resections. Co-author DOI 10.1245/s10434-021-10560-7↗
  48. Laparoscopic Radical Antegrade Modular Pancreatosplenectomy with Anterocranial Splenic Artery-First Approach for Left-Sided Resectable Pancreatic Cancer (with … Co-author DOI 10.1245/s10434-022-11382-x↗
  49. Prediction of Recurrence Pattern of Pancreatic Cancer Post-Pancreatic Surgery Using Histology-Based Supervised Machine Learning Algorithms: A Single-Center Ret… Co-author DOI 10.1245/s10434-022-11471-x↗
  50. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOL… Co-author DOI 10.1245/s10434-022-11503-6↗

Closest collaborators

The 25 strongest of 178 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yosuke Inoue · 35 shared papers, 2019–2026 · strength 6.14
  2. Hiromichi Ito · 30 shared papers, 2019–2026 · strength 5.42
  3. Yu Takahashi · 30 shared papers, 2019–2026 · strength 5.16
  4. Yoshihiro Ono · 27 shared papers, 2019–2026 · strength 4.88
  5. Naoki Sasahira · 16 shared papers, 2022–2026 · strength 2.83
  6. Masato Ozaka · 14 shared papers, 2022–2026 · strength 2.57
  7. Akio Saiura · 16 shared papers, 2019–2024 · strength 2.41
  8. Richard David Schulick · 13 shared papers, 2020–2026 · strength 2.07
  9. Takashi Sasaki · 12 shared papers, 2022–2026 · strength 2.06
  10. Aya Maekawa · 10 shared papers, 2023–2026 · strength 2.02
  11. Marco Del Chiaro · 12 shared papers, 2020–2026 · strength 1.83
  12. Kojiro Omiya · 9 shared papers, 2023–2026 · strength 1.76
  13. Manabu Takamatsu · 8 shared papers, 2022–2025 · strength 1.41
  14. Sohei Satoi · 8 shared papers, 2022–2026 · strength 1.34
  15. Takafumi Mie · 7 shared papers, 2022–2025 · strength 1.32
  16. Yoshihiro Ono · 6 shared papers, 2023–2025 · strength 1.25
  17. Marc G. Besselink · 6 shared papers, 2022–2026 · strength 1.10
  18. Daisuke Hashimoto · 6 shared papers, 2023–2026 · strength 1.02
  19. Tomotaka Kato · 5 shared papers, 2022–2026 · strength 1.02
  20. Thomas F. Stoop · 5 shared papers, 2023–2026 · strength 0.99
  21. Tatsunori Miyata · 4 shared papers, 2026 · strength 0.97
  22. Y. H. Andrew Wu · 6 shared papers, 2021–2023 · strength 0.95
  23. Yosuke Inoue · 5 shared papers, 2023–2026 · strength 0.92
  24. So Yamaki · 5 shared papers, 2023–2026 · strength 0.90
  25. Yuki Hirose · 5 shared papers, 2023–2025 · strength 0.87

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.